Clifford Stocks

Clifford J. Stocks is a seasoned executive with over three decades of experience in the biotech industry. As the Founder and Chief Executive Officer of OncoResponse, Inc., he has a strong background in immuno-oncology and cancer treatment, with a focus on therapeutic antibodies. Prior to his current role, Clifford led Theraclone Sciences, Inc. in Seattle Washington, a company specializing in infectious disease treatment. His successful track record includes key contributions at Calistoga Pharmaceuticals, where he played a pivotal role in the development of the PI3K inhibitor, idelalisib, leading to its acquisition by Gilead for $600 million. With expertise in business and corporate development, strategy, and deal-making, Clifford's career highlights encompass leadership positions at ICOS Corporation, where he was instrumental in the development and launch of Cialis® and the Lilly ICOS joint venture merger. His academic background includes research in immunology and molecular genetics, coupled with an MBA from The University of Chicago Booth School of Business.